Emerging roles of microRNAs in EGFR-targeted therapies for lung cancer

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Han, Fei ^a   He, Jinxi ^a   Li, Feng ^a   Yang, Jiali ^a   Wei, Jun ^a   Cho, William C ^b   Liu, Xiaoming ^a,c  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c NINGXIA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MICRORNA; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; GENETIC MARKER;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; DOWN REGULATION; DRUG TARGETING; HUMAN; LUNG CANCER; MOLECULARLY TARGETED THERAPY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; ANTAGONISTS AND INHIBITORS; GENETIC MARKER; GENETICS; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; GENETIC MARKERS; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84939134683     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/672759     Document Type: Article

References (70)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward, "Cancer statistics, 2010," CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277-300, 2010.
2. Y. Wang, G. Deng, X. Liu, and W. C. Cho, "Monoclonal antibodies in lung cancer," Expert Opinion on BiologicalTherapy, vol. 13, no. 2, pp. 209-226, 2013.
3. J. E. Larsen, T. Cascone, D. E. Gerber, J. V. Heymach, and J. D. Minna, "Targeted therapies for lung cancer: clinical experience and novel agents," Cancer Journal, vol. 17, no. 6, pp. 512-527, 2011.
4. R. S. Heist and D. Christiani, "EGFR-targeted therapies in lung cancer: predictors of response and toxicity," Pharmacogenomics, vol. 10, no. 1, pp. 59-68, 2009.
5. T. Yoshida, G. Zhang, and E. B. Haura, "Targeting epidermal growth factor receptor: central signaling kinase in lung cancer," Biochemical Pharmacology, vol. 80, no. 5, pp. 613-623, 2010.
6. P. A. Janne, J. A. Engelman, and B. E. Johnson, "Epidermal growth factor receptormutations in non-small-cell lung cancer: implications for treatment and tumor biology," Journal of Clinical Oncology, vol. 23, no. 14, pp. 3227-3234, 2005.
7. R. Perez, T. Crombet, J. de Leon, and E. Moreno, "A view on EGFR-targeted therapies from the oncogene-addiction perspective," Frontiers in Pharmacology, vol. 4, article 53, 2013.
8. J. Remon, T. Moran, M. Majem et al., "Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins," Cancer Treatment Reviews, vol. 40, no. 1, pp. 93-101, 2014.
9. H. A. Yu, G. J. Riely, and C. M. Lovly, "Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors," Clinical Cancer Research, vol. 20, no. 23, pp. 5898-5907, 2014.
10. Y. Lin, X. Wang, and H. Jin, "EGFR-TKI resistance in NSCLC patients: mechanisms and strategies," The American Journal of Cancer Research, vol. 4, no. 5, pp. 411-435, 2014.
11. M. Inui, G. Martello, and S. Piccolo, "MicroRNA control of signal transduction,"Nature ReviewsMolecular Cell Biology, vol. 11, no. 4, pp. 252-263, 2010.
12. I. Hoshino and H. Matsubara, "MicroRNAs in cancer diagnosis and therapy: frombench to bedside," Surgery Today, vol. 43, no. 5, pp. 467-478, 2013.
13. F. Wang, L. W. Chan, H. K. Law et al., "Exploring microRNAmediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases," Genomics, vol. 104, no. 6, pp. 504-511, 2014.
14. D. N. Hayes and H. L. McLeod, "EGFR regulation by microRNA in lung cancer: a rose by any other name . . . is an increasingly complicated rose," Annals of Oncology, vol. 19, no. 6, pp. 1036-1037, 2008.
15. G. J. Weiss, L. T. Bemis, E. Nakajima et al., "EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines," Annals of Oncology, vol. 19, no. 6, pp. 1053-1059, 2008.
16. G. G. Gomez, J. Wykosky, C. Zanca, F. B. Furnari, and W. K. Cavenee, "Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks," Cancer Biology and Medicine, vol. 10, no. 4, pp. 192-205, 2013.
17. R. M. Mader, S. Foerster, N. Sarin et al., "NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down-regulate microRNA related to epithelial-mesenchymal transition," International Journal of Clinical Pharmacology and Therapertics, vol. 52, no. 1, pp. 92-94, 2014.
18. L. W. C. Chan, F. F. Wang, and W. C. S. Cho, "Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer," Current Topics in Medicinal Chemistry, vol. 12, no. 8, pp. 920-926, 2012.
19. B. Kefas, J. Godlewski, L. Comeau et al., "microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma," Cancer Research, vol. 68, no. 10, pp. 3566-3572, 2008.
20. R. J. Webster, K. M. Giles, K. J. Price, P. M. Zhang, J. S. Mattick, and P. J. Leedman, "Regulation of epidermal growth factor receptor signaling in human cancer cells by MicroRNA-7," The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5731-5741, 2009.
21. Y.-T. Chou, H.-H. Lin, Y.-C. Lien et al., "EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF," Cancer Research, vol. 70, no. 21, pp. 8822-8831, 2010.
22. M. M. Bjaanaes, A. R. Halvorsen, S. Solberg et al., "Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas," International Journal of Cancer, vol. 135, no. 8, pp. 1812-1821, 2014.
23. S. Dacic, L. Kelly, Y. Shuai, and M. N. Nikiforova, "miRNA expression profiling of lung adenocarcinomas: correlation with mutational status," Modern Pathology, vol. 23, no. 12, pp. 1577-1582, 2010.
24. G. Yamaguchi, M. Takanashi, M. Tanaka et al., "Isolation of miRNAs that target EGFR mRNA in human lung cancer," Biochemical and Biophysical ResearchCommunications, vol. 420, no. 2, pp. 411-416, 2012.
25. L.-K. Wang, T.-H. Hsiao, T.-M. Hong et al., "MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma," PLoS ONE, vol. 9, no. 5, Article ID e96765, 2014.
26. M. Seike, A. Goto, T. Okano et al., "miR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 12085-12090, 2009.
27. Y. H. Guo, C. Zhang, J. Shi et al., "Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR through the ERK1/2 in non-small cell lung cancer," Oncology Reports, vol. 31, no. 4, pp. 1940-1946, 2014.
28. Y.-L. Wu, C. Zhou, C.-P. Hu et al., "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial," The Lancet Oncology, vol. 15, no. 2, pp. 213-222, 2014.
29. K.-Y. Su, H.-Y. Chen, K.-C. Li et al., "Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer," Journal of Clinical Oncology, vol. 30, no. 4, pp. 433-440, 2012.
30. Y. Shen, D. Tang, R. Yao et al., "MicroRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation," Medical Oncology, vol. 30, no. 4, article 750, 2013.
31. W. C. S. Cho, A. S. C. Chow, and J. S. K. Au, "MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1," RNA Biology, vol. 8, no. 1, pp. 125-131, 2011.
32. M. Garofalo, G. Romano, G. Di Leva et al., "EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers," Nature Medicine, vol. 18, no. 1, pp. 74-82, 2012.
33. B. Li, S. Ren, X. Li et al., "MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer," Lung Cancer, vol. 83, no. 2, pp. 146-153, 2014.
34. H. Zhang, Y. Su, F. Xu, J. Kong, H. Yu, and B. Qian, "Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers," PLoS ONE, vol. 8, no. 11, Article ID e81408, 2013.
35. F. Xu, H. Zhang, Y. Su, J. Kong, H. Yu, and B. Qian, "Upregulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers," Clinical and Translational Oncology, vol. 16, no. 11, pp. 980-985, 2014.
36. M. Acunzo, G. Romano, D. Palmieri et al., "Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 21, pp. 8573-8578, 2013.
37. W. Wang, B. Cheng, L. Miao, Y. Me, and M. Wu, "Mutant p53- R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression," Cell Death and Disease, vol. 4, no. 4, article e574, 2013.
38. G. Mudduluru, P. Ceppi, R. Kumarswamy, G. V. Scagliotti, M. Papotti, and H. Allgayer, "Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer," Oncogene, vol. 30, no. 25, pp. 2888-2899, 2011.
39. L. Liu, X. Shao, W. Gao et al., "MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor," The FEBS Journal, vol. 279, no. 20, pp. 3800-3812, 2012.
40. G. Chen, I. A. Umelo, S. Lv et al., "miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells," PLoS ONE, vol. 8, no. 3, Article ID e60317, 2013.
41. B. Xu, N. Wang, X. Wang et al., "miR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer," Prostate, vol. 72, no. 11, pp. 1171-1178, 2012.
42. M. Katakowski, X. Zheng, F. Jiang, T. Rogers, A. Szalad, and M. Chopp, "MiR-146b-5p suppresses EGFR expression and reduces In Vitro migration and invasion of glioma," Cancer Investigation, vol. 28, no. 10, pp. 1024-1030, 2010.
43. L. Adam, M. Zhong, W. Choi et al., "miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy," Clinical Cancer Research, vol. 15, no. 16, pp. 5060-5072, 2009.
44. Z. Zhang, Z.-B. Liu, W.-M. Ren, X.-G. Ye, and Y.-Y. Zhang, "The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells," International Journal of Molecular Medicine, vol. 30, no. 4, pp. 856-862, 2012.
45. H. Mataki, N. Seki, T. Chiyomaru et al., "Tumor-suppressive microRNA-206 as a dual inhibitor ofMET and EGFR oncogenic signaling in lung squamous cell carcinoma," International Journal of Oncology, vol. 46, no. 3, pp. 1039-1050, 2015.
46. X. Zhou, Y. Ren, L. Moore et al., "Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status," Laboratory Investigation, vol. 90, no. 2, pp. 144-155, 2010.
47. W. W. Du, L. Fang, M. Li et al., "MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling," Journal of Cell Science, vol. 126, no. 6, pp. 1440-1453, 2013.
48. H. Salim, N. S. Akbar, D. Zong et al., "MiRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence," British Journal of Cancer, vol. 107, no. 8, pp. 1361-1373, 2012.
49. K. Kitamura, M. Seike, T. Okano et al., "MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells,"Molecular CancerTherapeutics, vol. 13, no. 2, pp. 444-453, 2014.
50. Y.-F. Gu, H. Zhang, D. Su et al., "miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer," Chinese Medical Journal, vol. 126, no. 23, pp. 4435-4439, 2013.
51. J. Zhou, X. Chen, J. Zhao, Z. Bao, P. Zhang, and Z. Liu, "MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET," Cancer Letters, vol. 351, no. 2, pp. 265-271, 2014.
52. A. Ahmad, M. Y. Maitah, K. R. Ginnebaugh et al., "Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs," Journal ofHematology andOncology, vol. 6, no. 1, article 77, 2013.
53. Y. Gao, X. Fan, W. Li, W. Ping, Y. Deng, and X. Fu, "MiR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124," Biochemical and Biophysical Research Communications, vol. 446, no. 1, pp. 179-186, 2014.
54. M. Zhong, X. Ma, C. Sun, and L. Chen, "MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer," Chemico-Biological Interactions, vol. 184, no. 3, pp. 431-438, 2010.
55. C. G. Lee, S. McCarthy, M. Gruidl, C. Timme, and T. J. Yeatman, "MicroRNA-147 induces amesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance," PLoS ONE, vol. 9, no. 1, Article ID e84597, 2014.
56. J. L. Bryant, J. Britson, J. M. Balko et al., "A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT," British Journal of Cancer, vol. 106, no. 1, pp. 148-156, 2012.
57. E. Izumchenko, X. Chang, C. Michailidi et al., "The TGFbetamiR200- MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors," Cancer Research, vol. 74, no. 14, pp. 3995-4005, 2014.
58. Y. Wang, H. Xia, Z. Zhuang, L. Miao, X. Chen, and H. Cai, "Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer," Cell Death and Disease, vol. 5, no. 5, Article ID e1227, 2014.
59. K. Rai, N. Takigawa, S. Ito et al., "Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells," Molecular Cancer Therapeutics, vol. 10, no. 9, pp. 1720-1727, 2011.
60. J. Li, Y. Zheng, G. Sun, and S. Xiong, "Restoration of miR expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling," Oncology Reports, vol. 32, no. 6, pp. 2511-2516, 2014.
61. H.-S. Jeon, Y. H. Lee, S. Y. Lee et al., "A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population," Gene, vol. 534, no. 1, pp. 66-71, 2014.
62. J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling," Science, vol. 316, no. 5827, pp. 1039-1043, 2007.
63. M. Garofalo and C. M. Croce, "MicroRNAs:master regulators as potential therapeutics in cancer," Annual Review of Pharmacology and Toxicology, vol. 51, pp. 25-43, 2011.
64. K. Politi, P.-D. Fan, R. Shen, M. Zakowski, and H. Varmus, "Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma," Disease Models and Mechanisms, vol. 3, no. 1-2, pp. 111-119, 2010.
65. V. Del Vescovo, M. Grasso, M. Barbareschi, and M. A. Denti, "MicroRNAs as lung cancer biomarkers," World Journal of Clinical Oncology, vol. 5, no. 4, pp. 604-620, 2014.
66. I. S. Donev, W. Wang, T. Yamada et al., "Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer," Clinical Cancer Research, vol. 17, no. 8, pp. 2260-2269, 2011.
67. S. Cufi, R. Bonavia, A. Vazquez-Martin et al., "Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo," Scientific Reports, vol. 3, article 2459, 2013.
68. Z. Zhang, J. C. Lee, L. Lin et al., "Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer," Nature Genetics, vol. 44, no. 8, pp. 852-860, 2012.
69. W. C. S. Cho, "Targeting signaling pathways in lung cancer therapy," Expert Opinion on Therapeutic Targets, vol. 17, no. 2, pp. 107-111, 2013.
70. W. C. S. Cho, "MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy," International Journal of Biochemistry and Cell Biology, vol. 42, no. 8, pp. 1273-1281, 2010.